Potent antifungal agent, hosting defense peptide mimic through a membrane-active mechanism

Novel Histone deacetylase (HDAC) inhibotor, displays potent inhibitory activity towards human HDACs and several cancer cells lines

Novel HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9

Novel Selective Histone Deacetylase 8 (HDAC8) Inhibitor with Anti-Neuroblastoma Activity

First-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8)

Novel highly potent and selective HDAC6 inhibitor with an IC 50 of 2.54 nM and being more than 290- to 3300-fold selective over other HDAC isoforms

Potent and selective HDAC6 inhibitor

Potent and selective HDAC6 inhibitor

Novel HDAC6 isoform-selective inhibitor, increasing the acetylation level of α-tubulin with little effect on the acetylation of histone H3, inducing apoptosis in HL-60 cell by activating caspase 3

Novel potent HDAC6 inhibitor with an IC 50 of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3), displaying high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC

Novel hHDAC6 inhibitor, having low inhibitory potency over hHDAC1 and hHDAC8, as potential pharmacological tools for idiopathic pulmonary fibrosis (IPF) treatment

Novel potent and selective PROTAC degrader of HDAC6 protein

Novel PROTAC HDAC6 degrader, efficiently and selectively decreased HDAC6 levels in several cell lines, including activated THP-1 cells

High affinity and selective colchicine site tubuline inhibitor amenable to radiolabel with C-11, a positron emitting isotope

Novel Inhibitor of Hepatitis C Virus

Antiviral agent against HCV genotype 2a JFH-1 infected in human Huh7.5.1 cells

Novel copper-dependent cytotoxic agent, being highly potent against a panel of pancreatic, small cell lung carcinoma, prostate cancer, and leukemia models, with IC50 values in the low-to-mid nanomolar range

Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels.

Novel inhibitor of human coronavirus 229E (hCoV 229E) replication with an EC50 value of 5.5 µM

Novel Nek2 inhibitor, successfully mitigating drug resistance in bortezomib-resistant multiple myeloma; Potent AXL kinase inhibitor

Novel selective dual carbonic anhydrase IX and XII inhibitor

Novel inhibitor of human carbonic anhydrase XII (hCA-XII), demonstrating significant antiproliferative activity against hypoxic tumor cell lines

Novel inhibitor of DosRST, inhibiting Mtb survival during hypoxia-induced NRP, directly targeting the sensor kinase heme, via a mechanism that is distinct from the oxidation and alkylation of heme previously observed with artemisinin (HC101A)

Novel inhibitor of DosRST, inhibiting DosR DNA binding in a dose-dependent manner by directly targeting DosR

Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence

Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence

Hepatocellular carcinoma (HCC)-selective cytotoxin, suppressing AKT anti-apoptotic signaling

Precursor for HATRIC-based ligand receptor capture (HATRIC-LRC)

Novel p300/CBP HAT inhibitor

Natural antiproliferative, antifungal, antitumor agent, suppressing the epithelial-mesenchymal transition (EMT) process and inhibiting activation of the FAK/Src/STAT3 signaling pathway in A375 cells, targeting RACK1 to suppress cancer cell migration